On November 1, 2023, VYNE Therapeutics Inc. closed the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.89 USD | +6.64% | +15.48% | +24.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.89% | 38.21M | |
+33.38% | 690B | |
+26.43% | 546B | |
-5.25% | 358B | |
+19.54% | 323B | |
+4.74% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.23% | 161B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors